Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nigel Bundred

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Breast Cancer Research and Treatment|May 17, 2024
BE-WEL trial (breast: evaluation of weight and exercise for lymphoedema) testing weight control and exercise programmes for women with breast cancer related lymphoedema: a feasibility trialMichelle Harvie, Karen Livingstone, Debbie McMulllan, et al.
BMJ (Clinical Research Ed.)|March 2, 2002
Costs and benefits of a one stop clinic compared with a dedicated breast clinic: randomised controlled trialPaola Dey, Nigel Bundred, Alan Gibbs, et al.
The Oncologist|June 3, 2008
Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozoleAdam Brufsky, Nigel Bundred, Robert Coleman, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|September 10, 2020
Do surgical margins matter after mastectomy? A systematic reviewJames Bundred, Sarah Michael, Sarah Bowers, et al.
Investigational New Drugs|January 15, 2013
Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgeryNigel Bundred, Janis Gardovskis, Janusz Jaskiewicz, et al.
British Journal of Cancer|May 5, 2020
Increases in arm volume predict lymphoedema and quality of life deficits after axillary surgery: a prospective cohort studyNigel Bundred, Phil Foden, Chris Todd, et al.
The Journal of Biological Chemistry|May 16, 2002
Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptorAndrew P Gilmore, Anthony J Valentijn, Pengbo Wang, et al.
British Journal of Cancer|August 2, 2019
The effectiveness of home versus community-based weight control programmes initiated soon after breast cancer diagnosis: a randomised controlled trialMichelle Harvie, Mary Pegington, Debbie McMullan, et al.
Lancet (London, England)|December 22, 2015
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trialJohn F Forbes, Ivana Sestak, Anthony Howell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2014
Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)Alexandra Leary, Abigail Evans, Stephen R D Johnston, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Breast Cancer Research and Treatment|May 17, 2024
BE-WEL trial (breast: evaluation of weight and exercise for lymphoedema) testing weight control and exercise programmes for women with breast cancer related lymphoedema: a feasibility trialMichelle Harvie, Karen Livingstone, Debbie McMulllan, et al.
BMJ (Clinical Research Ed.)|March 2, 2002
Costs and benefits of a one stop clinic compared with a dedicated breast clinic: randomised controlled trialPaola Dey, Nigel Bundred, Alan Gibbs, et al.
The Oncologist|June 3, 2008
Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozoleAdam Brufsky, Nigel Bundred, Robert Coleman, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|September 10, 2020
Do surgical margins matter after mastectomy? A systematic reviewJames Bundred, Sarah Michael, Sarah Bowers, et al.
Investigational New Drugs|January 15, 2013
Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgeryNigel Bundred, Janis Gardovskis, Janusz Jaskiewicz, et al.
British Journal of Cancer|May 5, 2020
Increases in arm volume predict lymphoedema and quality of life deficits after axillary surgery: a prospective cohort studyNigel Bundred, Phil Foden, Chris Todd, et al.
The Journal of Biological Chemistry|May 16, 2002
Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptorAndrew P Gilmore, Anthony J Valentijn, Pengbo Wang, et al.
British Journal of Cancer|August 2, 2019
The effectiveness of home versus community-based weight control programmes initiated soon after breast cancer diagnosis: a randomised controlled trialMichelle Harvie, Mary Pegington, Debbie McMullan, et al.
Lancet (London, England)|December 22, 2015
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trialJohn F Forbes, Ivana Sestak, Anthony Howell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2014
Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)Alexandra Leary, Abigail Evans, Stephen R D Johnston, et al.
Pageof 4